Sulphonylureas monotherapy and risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: A population‐based cohort study in China
12
Citation
45
Reference
10
Related Paper
Citation Trend
Abstract:
Abstract Purpose The risk of heart failure associated with sulphonylureas is unclear. We evaluated the association between sulphonylureas and hospitalization of heart failure (HHF) in patients with type 2 diabetes mellitus (T2DM) in China. Methods A retrospective cohort study was implemented using the Yinzhou Regional Health Care Database (YRHCD). We identified 15 752 adult patients with T2DM who were newly exposed to sulphonylurea monotherapy (N = 12 487) or acarbose monotherapy (N = 3265) from January 2010 to September 2016. Cox proportional hazards models weighted by inverse probability of treatment weights were used to compare the risk of HHF between initiators of sulphonylurea and acarbose. Results During a median follow‐up of 0.55 (0.49, 1.11) and 0.49 (0.35, 0.70) years for sulphonylureas and acarbose initiators separately, 320 patients developed HHF, with 279 events in sulphonylureas group, and 41 events in acarbose group. The incidence rates of HHF among sulphonylureas initiators and acarbose initiators were 22.2 (95% CI 19.6‐24.9) and 18.3 (95% CI 13.2‐24.9) per 1000 person‐years, respectively. The adjusted hazard ratio (aHR) of HHF for sulphonylureas vs acarbose was 1.61 (95% CI 1.14‐2.27). When stratified by history of heart failure, aHR was 1.55 (95% CI 0.79‐3.06) in patients with a history of heart failure, and 1.64 (95% CI 1.10‐2.45) in patients with no history of heart failure. Conclusions Our study suggested that use of sulphonylureas monotherapy compared with acarbose monotherapy for initial treatment of T2DM for approximately 0.5 years are significantly associated with a higher risk of HHF.Keywords:
Acarbose
Cite
Objective To observe glimepiride and acarbose treatment on 60 cases with type 2 diabetes mellitus(T2DM).Method Glimepiride and acarbose were used 12 weeks in 60 patients with T2DM.Results TG,TC,LDL-C,FBG,2hPG and HbA1c decreased while HDL-C incressed after treatment(P 0.05);HOMA-IR was improved more significantly(P 0.05).Conclusion Glimepiride and acarbose to treat T2DM have satisfactory effects in glucose,blood lipids and HOMA-IR.
Glimepiride
Acarbose
Cite
Citations (0)
The ability of Acarbose to improve the metabolic control of type II diabetics has been studied in a double blind study. 28 patients, poorly controlled despite maximal oral treatment and diet received 4 months of Acarbose (n = 15) or Placebo (n = 13). After 4 months of Acarbose post prandial blood glucose levels were significantly reduced at 10 and 14 hours compared to baseline values (p less than 0.05). Nevertheless, the metabolic control of Acarbose and Placebo groups was not statistically different at the end of the study. The beneficial effect of Acarbose appears to be slight but this may be due to 1) the relatively low dosage of acarbose used, 2) the importance of carbohydrate restriction, or, more probably, 3) the selection of the patients as most of them might have been classified as insulin requiring diabetics.
Acarbose
Metabolic control analysis
Cite
Citations (18)
Background Although most people with relapsing onset multiple sclerosis (R-MS) eventually transition to secondary progressive multiple sclerosis (SPMS), little is known about disability progression in SPMS. Methods All R-MS patients in the Cardiff MS registry were included. Cox proportional hazards regression was used to examine a) hazard of converting to SPMS and b) hazard of attaining EDSS 6.0 and 8.0 in SPMS. Results 1611 R-MS patients were included. Older age at MS onset (hazard ratio [HR] 1.02, 95%CI 1.01–1.03), male sex (HR 1.71, 95%CI 1.41–2.08), and residual disability after onset (HR 1.38, 95%CI 1.11–1.71) were asso- ciated with increased hazard of SPMS. Male sex (EDSS 6.0 HR 1.41 [1.04–1.90], EDSS 8.0 HR 1.75 [1.14–2.69]) and higher EDSS at SPMS onset (EDSS 6.0 HR 1.31 [1.17–1.46]; EDSS 8.0 HR 1.38 [1.19–1.61]) were associated with increased hazard of reaching disability milestones, while older age at SPMS was associated with a lower hazard of progression (EDSS 6.0 HR 0.94 [0.92–0.96]; EDSS 8.0: HR 0.92 [0.90–0.95]). Conclusions Different factors are associated with hazard of SPMS compared to hazard of disability progres- sion after SPMS onset. These data may be used to plan services, and provide a baseline for comparison for future interventional studies and has relevance for new treatments for SPMS RobertsonNP@cardiff.ac.uk
Cite
Citations (0)
Objective To observe the effect of acarbose and metformin on patients with impaired glucose tolerance(IGT).Methods Tofal 82 patients with IGT were randomly divided into two groups(acarbose group and metformin group).Acarbose group took acarbose 50~100mg,three times per day.Metformin group took metformin 250~500mg,three times per day.The study lasted for 12 months.Deteminating FPG、2hPG、TC、TG and HDL before and after the study.Results Both FPG and 2hPG significantly decreased in two groups(P0.05 and P0.01).But 2hPG significantly decreased in acarbose group compaired with that of metformin group(P0.01).TC、TG significantly decreased and HDL significantly increased in two groups,but there were no significant difference in two group.Metformin group can significantly decreased BMI compaired with acarbose group(P0.05).Conclusion Acarbose and metformin can be used to treat IGT patients.
Acarbose
Cite
Citations (0)
Acarbose摂取および摂取中止後の小腸二糖類水解酵素の変化について雄ラットを用いて観察を行なった。1) 対照群 (I群), Acarbose群 (II群) およびAcarbose投与中止群 (III群) の3群間において, 体重はII, III群がI群に比較して有意に減少していた。さらに, 尿量はII群がI群に比較して減少する傾向が観察され, またII群とIII群との間で有意差があり, Acarbose摂取中止により尿量はI群のレベルにまで戻ることが観察された。摂食量, 飲水量, ならびに糞量はII群において対照群に比較して有意に増加していた。糞中の水分の割合は, II群においてI群の約3倍量に増加していた。一方, 皿群では, 飲水量, 糞量はI群と同レベルに戻ることが観察された。2) 結腸および盲腸の重量はAcarbose摂取により有意に増加した。しかし, この影響はAcarbose摂取を中止するともとに戻り, 可逆的であった。3) Acarbose摂取により, マルターゼ活性は対照群に比較して有意な低下が観察された。4) Acarboseによるマルターゼ活性の阻害形式は, in vitroにおいて拮抗形であり, K1値は8.56×10-7Mであった。また, in vivoの場合は対照群と比較し, Vmax値のみ低下し, Km値は変化しなかった。
Acarbose
Disaccharidase
Cite
Citations (0)
Acarbose is a potent glycosidase inhibitor widely used in the clinical treatment of type 2 diabetes mellitus (T2DM). Various acarbose analogs have been identified while exploring compounds with improved pharmacological properties. In this study, we found that AcbE from Actinoplanes sp. SE50/110 catalyzes the production of acarbose analogs that exhibit significantly improved inhibitory activity towards α-amylase than acarbose. Recombinant AcbE mainly catalyzed the formation of two new compounds, namely acarstatins A and B, using acarbose as substrate. Using high-resolution mass spectrometry, nuclear magnetic resonance, and glycosidase hydrolysis, we elucidated their chemical structures as O-α-d-maltosyl-(1 → 4)-acarbose and O-α-d-maltotriosyl-(1 → 4)-acarbose, respectively. Acarstatins A and B exhibited 1584- and 1478-fold greater inhibitory activity towards human salivary α-amylase than acarbose. Furthermore, both acarstatins A and B exhibited complete resistance to microbiome-derived acarbose kinase 1-mediated phosphorylation and partial resistance to acarbose-preferred glucosidase-mediated hydrolysis. Therefore, acarstatins A and B have great potential as candidate therapeutic agents for T2DM.
Acarbose
Cite
Citations (1)
The hazard ratio and median survival time are the routine indicators in survival analysis. We briefly introduced the relationship between hazard ratio and median survival time and the role of proportional hazard assumption. We compared 110 pairs of hazard ratio and median survival time ratio in 58 articles and demonstrated the reasons for the difference by examples. The results showed that the hazard ratio estimated by the Cox regression model is unreasonable and not equivalent to median survival time ratio when the proportional hazard assumption is not met. Therefore, before performing the Cox regression model, the proportional hazard assumption should be tested first. If proportional hazard assumption is met, Cox regression model can be used; if proportional hazard assumption is not met, restricted mean survival times is suggested.风险比（hazard ratio，HR）和中位生存时间是生存分析时的常规分析和报告指标。本文简要介绍了HR和中位生存时间的关系以及比例风险假定在这两者之间的作用，分析了检索出的58篇文献中的110对风险比和中位生存时间比的差异，并通过实例阐明了产生这种差异的原因。结果表明，在不满足比例风险假定时，Cox回归模型计算得到的风险比是不合理的，且与中位生存时间之比不等价。因此，在使用Cox回归模型前，应先进行比例风险假定的检验，只有符合比例风险假定时才能使用该模型；当不符合比例风险假定时，建议使用限制性平均生存时间。.
Cite
Citations (0)
To study the impact of Acarbose combined with insulin in the treatment of diabetes. Acarbose was given to the patients with insulin therapy whose FBG was normal and PBG was high, and study the change of BG and HbA1c. Acarbose can decrease the level of PBG and HbA1c being (7.7 ±0.8) % vs being (7.3±0.6) %,( P 0.05). [Conclusion] Combined Acarbose with insulin is a good method to control the all-day blood glucose.
Acarbose
Cite
Citations (0)
Introduction: Acarbose, an anti-diabetic drug, is commonly used to treat diabetes mellitus type 2. Determinationof acarbose is crucial for routine quality control of acarbose tablets. Materials and Methods: In this report, a rapid, stable and precise method was developed and validated for the quantification of acarbose in tablets by 1H NMR. Two characteristic signals at 5.80 and 2.31 ppm were used to determine acarbose. The assay was linear over a concentration range of 0.25-10.0 mg/mL. The precision was 0.26% and 1.02% for signals at 5.80 and 2.31 ppm, respectively. The average recoveries of acarbose were 99.7% and 99.2%, with RSD values 0.51% and 0.61% at two signals, respectively. Results and Discussion: The content of tested tablets was 100.4% and 100.8% of the label claim with RSD values 0.96% and 1.47% at two signals, which met the requirement of Chinese Pharmacopoeia criteria for content uniformity of tablets. The assay has been successfully applied to determine the content of acarbose in tablets for quality evaluation. Conclusion: This method has been successfully applied to determine the content of acarbose in tablets for quality evaluation.
Acarbose
Cite
Citations (2)
AIM: To compare the efficacy of acarbose and metformin in treating non insulin dependent diabetes mellitus (NIDDM). METHODS: Sixty patients with NIDDM were divided into two groups. Thirty patients (M15, F15; age 61 a± s 13 a) were treated with acarbose 50-100 mg po , tid×6 wk; and after 30 patients (M16, F14; age 60±12 a) with metformin 250-500 mg, po , tid×6 wk as control. RESULTS: The fasting and 2 h postprandial blood glucose were remarkably lowered after therapy by acarbose and metformin. The effective rate of acarbose were 83 % and 97 %; and the effective rate of metformin were 87 % and 73 %. Acarbose was superior to metformin (in reducing 2 h postprandial blood glucose, P 0.01). And acarbose aws worse than metformin in lowering total cholesterol (TC)( P 0.01). The rates of adverse reaction were respectively 17 % and 11 %. CONCLUSION: Acarbose is a safe and effective drug in the treatment of NIDDM.
Acarbose
Cite
Citations (0)